David DeWorsop1, Gina Creatura1, Grai Bluez1, Halle Thurnauer1, Kimberlee Forselius-Bielen1, Mohini Ranganathan1, Emma Deaso1, Jasra Ali Bhat1, Deepak Cyril D'Souza2. 1. Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 2. Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: deepak.dsouza@yale.edu.
Abstract
OBJECTIVE: Medication nonadherence is a serious issue in clinical trials, especially in studies of substance abuse disorders. Measuring and confirming adherence is critical to ensuring that collected data is accurate and interpretable. This study evaluated the feasibility and success of a smartphone-based approach (Cellphone Assisted Remote Observation of Medication Adherence [CAROMA]) to visually confirm medication adherence in a clinical trial. METHOD:Medication adherence was confirmed visually via smartphones provided to participants in a double-blind, randomized, placebo-controlled trial for cannabis dependence. Every morning, subjects (n=20) were video-called by staff who observed consumption of study medication. Adherence was also assessed with weekly face-to-face visits, pill counts and plasma drug levels. Subjects were paid for completing daily CAROMA visits, and for returning the smartphone at study completion. RESULTS: CAROMA confirmed 96.04% adherence to medication. Concordance between expected and actual remaining study medication counted at weekly study visits was 87.69%. Subjects assigned to active study medication had detectable plasma drug levels, while those assigned to placebo did not. CAROMA was estimated to cost approximately $100 per subject per week - a total of $300.24 per subject for the 3-week outpatient portion of the trial. CONCLUSION: This pilot study demonstrates the feasibility, success and cost-effectiveness of CAROMA to facilitate and confirm medication adherence in a clinical trial. Preliminary findings support larger and longer studies, and possibly applying this approach to clinical care - especially in other populations with high rates of medication nonadherence.
RCT Entities:
OBJECTIVE: Medication nonadherence is a serious issue in clinical trials, especially in studies of substance abuse disorders. Measuring and confirming adherence is critical to ensuring that collected data is accurate and interpretable. This study evaluated the feasibility and success of a smartphone-based approach (Cellphone Assisted Remote Observation of Medication Adherence [CAROMA]) to visually confirm medication adherence in a clinical trial. METHOD: Medication adherence was confirmed visually via smartphones provided to participants in a double-blind, randomized, placebo-controlled trial for cannabis dependence. Every morning, subjects (n=20) were video-called by staff who observed consumption of study medication. Adherence was also assessed with weekly face-to-face visits, pill counts and plasma drug levels. Subjects were paid for completing daily CAROMA visits, and for returning the smartphone at study completion. RESULTS: CAROMA confirmed 96.04% adherence to medication. Concordance between expected and actual remaining study medication counted at weekly study visits was 87.69%. Subjects assigned to active study medication had detectable plasma drug levels, while those assigned to placebo did not. CAROMA was estimated to cost approximately $100 per subject per week - a total of $300.24 per subject for the 3-week outpatient portion of the trial. CONCLUSION: This pilot study demonstrates the feasibility, success and cost-effectiveness of CAROMA to facilitate and confirm medication adherence in a clinical trial. Preliminary findings support larger and longer studies, and possibly applying this approach to clinical care - especially in other populations with high rates of medication nonadherence.
Authors: Deepak Cyril D'Souza; Richard E Carson; Naomi Driesen; Jason Johannesen; Mohini Ranganathan; John H Krystal Journal: Biol Psychiatry Date: 2018-01-31 Impact factor: 13.382
Authors: Rachel L Tomko; Erin A McClure; Lindsay M Squeglia; Hayley Treloar Padovano; Aimee L McRae-Clark; Nathaniel L Baker; Matthew J Carpenter; Kevin M Gray Journal: Curr Opin Psychol Date: 2019-01-28
Authors: Joy M Schmitz; Scott D Lane; Michael F Weaver; Ponnada A Narayana; Khader M Hasan; DeLisa D Russell; Robert Suchting; Charles E Green Journal: Contemp Clin Trials Date: 2021-10-22 Impact factor: 2.226
Authors: Frances R Levin; John J Mariani; Martina Pavlicova; C Jean Choi; Amy L Mahony; Daniel J Brooks; Adam Bisaga; Elias Dakwar; Kenneth M Carpenter; Nasir Naqvi; Edward V Nunes; Kyle Kampman Journal: Drug Alcohol Depend Date: 2019-11-01 Impact factor: 4.492
Authors: Jackson M Steinkamp; Nathaniel Goldblatt; Jacob T Borodovsky; Amy LaVertu; Ian M Kronish; Lisa A Marsch; Zev Schuman-Olivier Journal: JMIR Ment Health Date: 2019-03-12
Authors: Holly Tibble; James Lay-Flurrie; Aziz Sheikh; Rob Horne; Mehrdad A Mizani; Athanasios Tsanas Journal: BMC Med Res Methodol Date: 2020-12-10 Impact factor: 4.615
Authors: Jennifer Dahne; Rachel L Tomko; Erin A McClure; Jihad S Obeid; Matthew J Carpenter Journal: Nicotine Tob Res Date: 2020-12-12 Impact factor: 4.244